These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18362263)

  • 1. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X; Phelip JM
    Arch Intern Med; 2008 Mar; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate in inflammatory bowel disease.
    Feagan BG; Alfadhli A
    Gastroenterol Clin North Am; 2004 Jun; 33(2):407-20, xi. PubMed ID: 15177546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?].
    Gomollón F; Gisbert JP
    Gastroenterol Hepatol; 2010 Jan; 33(1):43-53. PubMed ID: 19616870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of IBD in 2009.
    Harris A; Feller ER; Shah SA
    Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
    [No Abstract]   [Full Text] [Related]  

  • 6. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
    Rogler G
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppresive therapy for inflammatory bowel disease.
    Casis Herce B
    Rev Esp Enferm Dig; 2003 Jul; 95(7):456-8, 453-5. PubMed ID: 12952507
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term treatment of Crohn's disease with methotrexate, or, why's a nice drug like you still a wannabe in the treatment of inflammatory bowel disease?
    Kozarek RA
    Am J Gastroenterol; 2000 Jul; 95(7):1619-20. PubMed ID: 10925959
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 12. [Methotrexate in the treatment of inflammatory intestinal diseases].
    Díaz Blasco J; García Valriberas R
    Rev Esp Enferm Dig; 1997 May; 89(5):385-90. PubMed ID: 9280428
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment failure with rituximab in a patient with pemphigus vulgaris.
    Weger W; Aberer E
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):387-9. PubMed ID: 18269618
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical management of the pregnant patient with inflammatory bowel disease.
    Steinlauf AF; Present DH
    Gastroenterol Clin North Am; 2004 Jun; 33(2):361-85, xi. PubMed ID: 15177544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
    Lichtenstein GR; Sbreu MT; Cohen R; Tremaine W
    Rev Gastroenterol Mex; 2006; 71(3):351-401. PubMed ID: 17140062
    [No Abstract]   [Full Text] [Related]  

  • 16. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
    Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604.
    Caspersen S; Mortensen C; Riis L; Jess T; Bendtsen F
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1257. PubMed ID: 19778634
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inflammatory bowel diseases].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2005 Jan; 1(3):218-20, 223-7. PubMed ID: 15770816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome.
    Moosig F; Gross WL; Herrmann K; Bremer JP; Hellmich B
    Ann Intern Med; 2011 Sep; 155(5):341-3. PubMed ID: 21893636
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of infliximab in inflammatory bowel disease needs to be debated.
    de Vries HS; Van Oijen MG; de Jong DJ
    Clin Gastroenterol Hepatol; 2009 May; 7(5):603-4. PubMed ID: 19166980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.